NASDAQ:LNTH - Lantheus Stock Price, Forecast & News

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Lantheus Holdings Inc (NASDAQ:LNTH) posted its earnings results on Thursday, October, 31st. The medical equipment provider reported $0.28 EPS for the quarter, beating analysts' consensus estimates of $0.21 by $0.07. The medical equipment provider had revenue of $85.80 million for the quarter, compared to the consensus estimate of $83.82 million. Lantheus had a net margin of 10.02% and a return on equity of 46.58%. The company's revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.24 EPS. View Lantheus' Earnings History.

Lantheus is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Lantheus.

Lantheus updated its fourth quarter earnings guidance on Thursday, October, 31st. The company provided earnings per share (EPS) guidance of $0.27-$0.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.34. The company issued revenue guidance of $89-$91 million, compared to the consensus revenue estimate of $92.84 million.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lantheus.

News stories about LNTH stock have been trending negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Lantheus earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave media headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Lantheus.

Lantheus saw a drop in short interest in November. As of November 15th, there was short interest totalling 1,210,000 shares, a drop of 9.7% from the October 31st total of 1,340,000 shares. Based on an average trading volume of 411,400 shares, the short-interest ratio is currently 2.9 days. Approximately 3.2% of the company's stock are short sold. View Lantheus' Current Options Chain.

Some companies that are related to Lantheus include Quidel (QDEL), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Heska (HSKA), Quotient (QTNT), Oxford Immunotec Global (OXFD), Meridian Bioscience (VIVO), Nymox Pharmaceutical (NYMX), Vermillion (VRML), ImmuCell (ICCC), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), GeneNews (GNWSF) and Arca Biopharma (ABIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include Mobileye (MBBYF), CBL & Associates Properties (CBL), Energy Transfer LP Unit (ET), Gerdau (GGB), Cypress Semiconductor (CY), Akorn (AKRX), Ares Capital (ARCC), Endocyte (ECYT), Exelixis (EXEL) and Paratek Pharmaceuticals (PRTK).

(LNTH) raised $75 million in an initial public offering on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

Lantheus' stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (3.76%), Vaughan Nelson Investment Management L.P. (3.49%), Tamarack Advisers LP (1.91%), Voya Investment Management LLC (1.68%), Rice Hall James & Associates LLC (1.09%) and Peregrine Capital Management LLC (0.56%). Company insiders that own Lantheus stock include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, John W Crowley, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno, Timothy G Healey and Tudor Brown. View Institutional Ownership Trends for Lantheus.

LNTH stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Vaughan Nelson Investment Management L.P., Dupont Capital Management Corp, Campbell & CO Investment Adviser LLC, Cadence Capital Management LLC, Hancock Whitney Corp, State Street Corp and Bowling Portfolio Management LLC. Company insiders that have sold Lantheus company stock in the last year include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno and Tudor Brown. View Insider Buying and Selling for Lantheus.

LNTH stock was bought by a variety of institutional investors in the last quarter, including Voya Investment Management LLC, Rice Hall James & Associates LLC, Russell Investments Group Ltd., State of New Jersey Common Pension Fund D, Tealwood Asset Management Inc., Hussman Strategic Advisors Inc., Chicago Equity Partners LLC and Squarepoint Ops LLC. View Insider Buying and Selling for Lantheus.

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LNTH stock can currently be purchased for approximately $20.24.

Lantheus has a market capitalization of $794.22 million and generates $343.37 million in revenue each year. The medical equipment provider earns $40.51 million in net income (profit) each year or $0.94 on an earnings per share basis. Lantheus employs 488 workers across the globe.View Additional Information About Lantheus.

The official website for Lantheus is http://www.lantheus.com/.

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]